



1634

Docket No. 2094/65503-B

In re application of: Elena Feinstein and Orna Mor

Serial No.: 09/825,682

Examiner: D. Johannsen

Filed: April 4, 2001

Group Art Unit: 1634

For: SEQUENCE CHARACTERISTICS OF BLADDER CANCER

RECEIVED

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SEP 17 2003

TECH CENTER 1600/2900

S I R:

Transmitted herewith is an amendment to the above-identified application.

\_\_\_\_ Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

\_\_\_\_ a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTIT
Total Claims	8	- * 25	= *** 0	x	\$9.00	\$18.00	= \$0.00
Independent Claims	1	- ** 13	= *** 0	x	\$42.00	\$84.00	= \$0.00
Multiple Dependent Claims(s) Presented <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				\$140.00	\$280.00		\$0.00
				TOTAL ADDITIONAL \$ 0.00 FEE			

\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\*If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

RECEIVED

SEP 17 2003

TECH CENTER 1600/2900

Amendment Transmittal Letter  
Page 2

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

Please charge Deposit Account No. \_\_\_\_\_  
in the amount of \$ \_\_\_\_\_.

A check in the amount of \$ \_\_\_\_\_ is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.


Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,




John P. White  
Registration No. 28,678  
Attorney for Applicant(s)  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

 9/12/03  
John P. White  
Reg. No. 28,678

Date



Docket No. 65503-B/JPW/FHB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elena Feinstein and Orna Mor

Serial No.: 09/825,682 Examiner: D. Johannsen

Filed : April 4, 2001 Group Art Unit: 1634

For : SEQUENCE CHARACTERISTICS OF BLADDER CANCER

1185 Avenue of the Americas  
New York, New York 10036  
September 12, 2003

**RECEIVED**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SEP 17 2003

Sir:

**TECH CENTER 1600/2900**

AMENDMENT AND RESPONSE TO JUNE 16, 2003 OFFICE ACTION

The Amendment is submitted in response to the Office Action issued by the U.S. Patent and Trademark Office on June 16, 2003 in connection with the above-identified application. A response to the June 16, 2003 Office Action is due September 16, 2003. Therefore, this Amendment is being timely filed.

In this Amendment, applicants have, without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application, canceled claims 7, 9-23, 25, and 28-29; and amended claims 1, 2, 4-6, 26, and 27.

**Amendments to the Claims** are reflected in the listing of claims 1-29, which begins on page 2 of this paper.

**Amendments to the Specification** begin on page 5 of this paper.

**Amendments to the Title** begin on page 6 of this paper.

**Remarks/Arguments** begin on page 7 of this paper.